An 8-year old child has difficulty walking and getting up from a squatting position. A muscle biopsy was done and is as shown in the image. Which of the following is true about this condition? [image]

Correct Answer: B. Death occurs in 3rd decade

The clinical presentation of difficulty walking and proximal muscle weakness in an 8-year-old child with muscle biopsy findings consistent with glycogen storage suggests Duchenne Muscular Dystrophy (DMD) or a glycogen storage myopathy. However, the specific mention of muscle biopsy with glycogen accumulation in a child with progressive proximal weakness and difficulty rising from squatting (Gower's sign) points to Pompe disease (Glycogen Storage Disease Type II). The natural history of infantile-onset Pompe disease shows progressive muscle weakness, respiratory compromise, and cardiac involvement. Without enzyme replacement therapy (ERT), patients typically die in the second to third decade due to respiratory failure and cardiomyopathy. The question states "death occurs in 3rd decade," which aligns with the untreated natural history of Pompe disease in childhood-onset cases. In India, where access to ERT (imiglucerase) is limited and expensive, most children with Pompe disease follow this natural history trajectory. The muscle biopsy showing glycogen accumulation with acid phosphatase-positive vacuoles is pathognomonic for lysosomal glycogen storage, confirming Pompe disease rather than other glycogenoses.

Why the other options are wrong

A. Previous history of viral prodrome — This is wrong because Pompe disease is a genetic lysosomal storage disorder caused by deficiency of acid α-glucosidase (GAA enzyme), not an acquired post-viral condition. While some inflammatory myopathies (viral myositis, dermatomyositis) may have viral prodrome, the biopsy findings of glycogen accumulation with acid phosphatase-positive vacuoles are diagnostic of a storage disorder, not inflammation. NBE may trap students who confuse acute myositis with chronic myopathies. C. Early treatment has excellent prognosis — This is wrong because while enzyme replacement therapy (imiglucerase) has improved outcomes in Pompe disease, it is not universally available in India due to cost (₹20–30 lakhs per year) and is often started late. Even with ERT, childhood-onset Pompe disease carries significant morbidity and mortality if started after age 8. The question asks about the natural history of the condition, not treatment outcomes. Early diagnosis and ERT initiation (ideally before age 6 months) have better prognosis, but this child is already 8 years old with established weakness. D. It is a mitochondrial storage disorder — This is wrong because Pompe disease is a lysosomal storage disorder, not mitochondrial. The enzyme deficiency (acid α-glucosidase) is lysosomal, and glycogen accumulates in lysosomes, not mitochondria. Mitochondrial myopathies (MELAS, MERRF) present with different biopsy findings (ragged-red fibers on Gomori trichrome stain) and have different inheritance patterns (maternal). This is a common NBE trap conflating different storage disorders.

High-Yield Facts

Mnemonics

GSD II = Pompe = Lysosomal (not mitochondrial) Glycogen Storage Disease II → Pompe → Lysosomal enzyme (acid α-glucosidase). Remember: Pompe = Proximal weakness + Older age of onset (late-onset form) + Muscle biopsy with glycogen + Progressive to 2nd–3rd decade + Enzyme replacement (ERT) is treatment. Lysosomal vs Mitochondrial Storage Lysosomal (Pompe, Gaucher, Niemann-Pick): Glycogen/lipid in lysosomes, acid phosphatase+, normal mitochondria. Mitochondrial (MELAS, MERRF): Ragged-red fibers, COX-negative, maternal inheritance. Use: When you see glycogen + acid phosphatase stain → think Pompe (lysosomal), NOT mitochondrial.

NBE Trap

NBE pairs "early treatment has excellent prognosis" with Pompe disease to trap students who conflate the theoretical benefit of ERT with real-world Indian clinical outcomes. At age 8 with established weakness, this child has already missed the critical window for ERT benefit (ideally started before age 6 months). The question tests knowledge of natural history without intervention, not treatment response.

Clinical Pearl

In Indian pediatric practice, Pompe disease is often diagnosed late (age 5–8 years) because newborn screening for GAA deficiency is not routine in most states. By the time diagnosis is made, the child has missed the critical window for ERT benefit, and the disease follows its natural history trajectory toward respiratory failure and death in the 2nd–3rd decade. Early recognition of proximal weakness + Gower's sign + glycogen-filled muscle biopsy should trigger immediate GAA enzyme and genetic testing.

_Reference: OP Ghai (Pediatrics) Ch. 8 (Inborn Errors of Metabolism); Robbins Ch. 5 (Glycogen Storage Diseases); Harrison Ch. 383 (Muscle Diseases)_